TY - JOUR A2 - Lazzeri，基娅拉AU - 昆卡，约翰A. AU - Laserna，安德烈斯AU - 雷耶斯，玛丽亚P. AU - 纳茨，约瑟夫L. AU - Botz，格雷戈里H. PY - 2020 DA - 2020/03 /25 TI - 一个HIV患者的急救入场糖尿病酮症酸中毒继发于Pembrolizumab SP - 8671530 VL - 2020 AB - 背景。Pembrolizumab是一个检查点抑制剂，其目标的程序性细胞死亡-1受体（PD-1），并已显示是对几种恶性肿瘤，包括肺癌有效。然而，危及生命的免疫相关的不良事件可能会导致从这些免疫疗法治疗。 病例报告。一名62岁的男子与艾滋病，肺转移性腺癌，并提交新发恶心，呕吐急诊科糖尿病的既往史，并且全身乏力。Glucose was 1191 mg/dl, hemoglobin A1c 11%, and potassium 6.9 mEq/L. He had metabolic acidosis with a lactate of 6.6 mmol/L and anion gap of 38 mEq/L, and ketones were detected on the urinalysis. Severe diabetic ketoacidosis was diagnosed, and the patient was admitted to the intensive care unit. Additional investigations showed low C-peptide and negative anti-glutamic acid decarboxylase antibody, anti-insulin antibody, and anti-islet-antigen 2Ab antibody. After ruling out other possible etiologies, pembrolizumab was considered to be the cause of the diabetes and ketoacidosis. 结论。如pembrolizumab与关卡抑制剂相关的威胁生命的不良事件呈上升趋势。我们建议密切跟踪和监测患者接受这些免疫疗法。这种策略可能会导致早期发现和预防，以及减少需要重症监护更严重的危及生命的并发症。SN - 2090-6420 UR - https://doi.org/10.1155/2020/8671530 DO - 10.1155 /八百六十七万一千五百三十〇分之二千零二十零JF - 病例报告重症监护PB - Hindawi出版KW - ER -